Remember
 
 
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.
     
 

August 8, 2016

SpeculatingStocks.com Stock Pick ► Akers Biosciences Inc. (AKER)

Stock Price: $3.13

Akers Biosciences Inc. engages in the developing, manufacturing, and supplying point of care screening and testing products.

AKER is a $16.98 million dollar company that recently released positive clinical trial results for its Chlamydia rapid test, based on its proprietary Particle ImmunoFiltration Assay (PIFA) technology. The Chlamydia rapid test is one of the several products Akers is planning to launch in the U.S. and international markets.

The product of pipeline of AKER includes other rapid tests for lung cancer, asthma, chronic obstructive pulmonary disease, diabetes and cardiac arrest. Late last month, AKER also announced another positive news piece with the signing of a distribution agreement with Aero-Med to distribute the Aker's BreathScan OxiChek disposable breathalyzer. The rapid test market is becoming hot in the United States and Akers Biosciences is set on penetrating the US market. The company also is gaining traction in China.

AKER is a relatively undiscovered nano-cap with revenue of $2.11 million last year. Cash, cash equivalents and short-term investments on the balance sheet were $2.62 million as of last quarter with no long-term debt.

AKER has trended up from approximately $1.30 in mid-February to $3.13 as of the close on August 8th. Investors could see AKER continue to climb as the company continues to place its products onto market with strong upside potential possible.

Speculative Score: 8

1 Being the Least Speculative and Most Confident

10 Being the Most Speculative and Possibly the Most Risky

 
     
Untitled Document